David Peltier is a research associate at TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks. He also doesn't invest in hedge funds or other private investment partnerships. Under no circumstances does the information in this column represent a recommendation to buy or sell stocks. Peltier appreciates your feedback; click here to send him an email.

If you liked this article you might like

Buy Stocks That Are Right for You: Cramer's 'Mad Money' Recap (Friday 2/16/18)

Buy Stocks That Are Right for You: Cramer's 'Mad Money' Recap (Friday 2/16/18)

Jim Cramer: These 4 Stocks Seem Attractive Right Here

Jim Cramer: These 4 Stocks Seem Attractive Right Here

Jim Cramer: Drug Stocks on the Move

Jim Cramer: Drug Stocks on the Move

The Decline In Johnson & Johnson Could Be Close to Being Over

The Decline In Johnson & Johnson Could Be Close to Being Over

Opioid Litigants Get Boost From Senate Report

Opioid Litigants Get Boost From Senate Report